Human 3 with Brom and Sam

I'm experimenting with a weekly livestream format where I respond to  short psychedelic articles / topics that don't warrant an entire video.   Plus I interact with the viewers and answer their questions about any  psychedelic topics.

Doug Drysdale is the CEO of Cybin, a psychedelic research company developing novel delivery systems for psilocybin, next-gen psychedelic  tryptamine molecules and performing studies on human brains under the influence of psychedelics using powerful brain imaging technology.  In this episode of the Integration Conversation, Brom and Doug cover all aspects of Cybin's business, and answer questions like:   

👇👇👇 Links 👇👇👇  

📺 Watch on YouTube:  https://youtu.be/cAsFHlVLpeA

💻 The Integration Co Website:  https:/theintegration.co  

📝 My notes on psychedelic investing:  https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf   

🎧 Listen on Spotify and other podcast platforms:  https://anchor.fm/theintegrationco  

🐦 brom on twitter:  https://twitter.com/therealbrom  

🎇 Clips and other stuff on Instagram:  https://instagram.com/theintegrationco  

💌 Email:   [email protected]  

⏰ Timestamps: 

🍄 Field Trip Health is the largest publicly traded, vertically integrated psychedelics company on the market.  Field Trip has a rapidly growing network of ketamine clinics and is developing novel psychedelic molecules and digital therapeutics.  In this deep dive episode, we interview Ronan Levy, the cofounder and executive chairman of field trip.  Ronan tells us:  

📺 Watch the video on YouTube:  https://youtu.be/8gtyZ8DWwNo

📝 My notes on psychedelic investing:  https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf   

🎧 Listen on Spotify and other podcast platforms:  https://anchor.fm/bromtalks   

🐦 brom on twitter:  https://twitter.com/therealbrom 

🎇 Clips and other stuff on Instagram:  https://instagram.com/bromtalks 

💌 Email:   [email protected]   

Disclaimer:  This video is not financial advice.  Brom holds shares in Field Trip Health, Mind Med, Cybin and Compass Pathways.

Atai Life Sciences is the most highly anticipated psychedelic IPO of 2021.  It has a pipeline of 10 drugs, owns a large piece of Compass Pathways, and is also researching digital therapeutics and brain computer interfaces.  When it IPOs it will likely be the psychedelic company with the largest market cap.  In this episode of Brom Talks, we peek behind the curtain of Atai, and try to see if this valuation is justified.  In doing so, we answer questions like:

Who is Christian Angermayer?  What does Atai's pipeline look like?  What are the implications of Atai's unorthodox corporate structure?  It is even fair to call Atai a psychedelics company?  And we also compare and contrast this company with MindMed.   

📝 My notes on psychedelic investing: 

https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf 

🎧 Listen on Spotify and other podcast platforms: 

https://anchor.fm/bromtalks 

📺YouTube:

https://www.youtube.com/c/bromtalks

🐦 brom on twitter: 

https://twitter.com/therealbrom

🎇 Clips and other stuff on Instagram: 

https://instagram.com/bromtalks

💌 Email:  

[email protected]

🍄 Wondering how to tell if a psychedelic stock is legit or full of shit?  This video describes how to research and understand both the psychedelic sector as a whole and individual psychedelic companies.  First we walk through my notes on investing in the psychedelic sector, and then look at 10 questions you should ask before investing in any psychedelic company.  We show how to use these questions to compare and contrast different psychedelic companies, and apply this methodology to Mind Medicine, Compass Pathways and Cybin.    

My notes on psychedelic investing: https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf   

Google Spreadsheet containing the 10 questions: 

https://docs.google.com/spreadsheets/d/1KIp_nd-OhyU5xx63oEMsKgU3XFZkkItl-aoyjCdItkg/edit?usp=sharing    

CLARIFICATIONS / CORRECTIONS 

📺 Watch on YouTube:  https://youtu.be/oA85Xzms8_U

🎇 Clips and other stuff on Instagram:  https://instagram.com/bromtalks​​  

🐦 brom on twitter: https://twitter.com/therealbrom​​  

⏰Timestamps:   

Disclaimer: This presentation is not financial advice.  You should not make any investment or trading decision based on the contents of this presentation.  Do not consider anything in this presentation to be professional advice.  Brom holds long positions in MindMed, Compass and Cybin as well as other psychedelic stocks.

🚀 Are you degen trader that's down 50% on a MindMed yolo?  I'm your stock therapist and I'm here to help you understand your emotions.  In this video I go over some basic behavioral economic concepts (like utility theory, risk aversion and risk seeking) and demonstrate how they apply to the psychology of traders using MindMed as a case study.      

Questions answered: 

Watch the vid @ https://youtube.com/c/bromtalks

🍄 Cybin Corp / Cybin Inc is a Psychedelics 2.0 company focused on new innovations in psychedelic drugs.  In this episode of Brom Talks, we investigate the Cybin team, go over their business lines, see what sets them apart from other psychedelic companies like MindMed and Compass.    We also answer questions like:  

Watch on YouTube: https://linktr.ee/therealbrom

Disclaimer: This presentation is not financial advice.  You should not make any investment or trading decision based on the contents of this presentation.  Do not consider anything in this presentation to be professional advice.  Brom holds long positions in Cybin as well as other psychedelic stocks.

🍄 Compass Pathways is the largest psychedelic stock by market cap, and was famously backed by Paypal and Palantir Founder Peter Thiel.  In this episode I investigate Compass Pathways and answer questions like:

📺Watch on YouTube:

https://youtu.be/ha2GMoZ7s60

📹 Clips Channel: 

https://www.youtube.com/channel/UCDzauugr4QA5dfcwaE1rweQ

🎇 Clips and other stuff on Instagram: 

https://instagram.com/bromtalks

🐦 brom on twitter:

https://twitter.com/therealbrom

Disclaimer: This recording is not financial advice.  You should not make any investment or trading decision based on the contents of this recording.  Do not consider anything in this video to be professional advice.  Brom holds long positions in Compass Pathways as well as other psychedelic stocks.

What is the true market cap potential for the medicinal psychedelic industry, and what's the best way to ride the shroom boom and invest in the psychedelic sector?  I show three different market cap estimates, discuss various pitfalls and caveats, and give my thoughts on how best to invest in this space.  Watch the video: https://youtu.be/jb949AKsYAA

Today we go deep into Numinus Wellness.  Numinus (also known as Numi) is a Canadian Psychedelic startup that many people think is undervalued.  This episode looks into this claim and tries to answer questions like:

You can watch this episode on YouTube https://youtu.be/jg2H0sMHZXg

See Brom's other links https://linktr.ee/therealbrom

Disclaimer:  This video is not financial advice.  Do you own research before buying or selling any stock, and talk to a financial advisor whos incentives are aligned with your own.  Brom owns shares of Numi as well as other psychedelic companies.